Triplet Therapeutics scores $59 mln

Cambridge, Massachusetts-based Triplet Therapeutics Inc, a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, has secured $59 million in financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this